FDA Authorizes 11 ZYN ULTRA Nicotine Pouches for Philip Morris
Event summary
- FDA issued Marketing Granted Orders for 11 ZYN ULTRA nicotine pouch products, including 9mg and 11mg variants.
- Additional 11mg variants remain under scientific review.
- ZYN ULTRA is free of tobacco-leaf and has higher moisture content.
- PMI leads the industry in securing FDA authorizations for smoke-free products.
- ZYN was the first nicotine pouch authorized for sale in the U.S. following rigorous scientific review.
The big picture
Philip Morris International continues to strengthen its position in the smoke-free products market with FDA authorizations for ZYN ULTRA nicotine pouches. This move aligns with the company's strategic shift towards smoke-free alternatives, which accounted for approximately 42% of PMI’s second-quarter 2026 total net revenues. The authorization underscores PMI's commitment to innovation and responsible marketing practices, reinforcing its role as a global smoke-free champion.
What we're watching
- Regulatory Dynamics
- How the FDA's ongoing review of additional ZYN ULTRA 11mg variants will impact PMI's product portfolio.
- Market Leadership
- Whether PMI can sustain its leadership in the smoke-free category amid increasing competition.
- Consumer Adoption
- The pace at which ZYN ULTRA products will be adopted by legal-age nicotine consumers.